Investigation of blood mRNA biomarkers for suicidality in an independent sample

N. Mullins; K. Hodgson; K. E. Tansey; N. Perroud; W. Maier; O. Mors; M. Rietschel; J. Hauser; N. Henigsberg; D. Souery; K. Aitchison; A. Farmer; P. McGuffin; G. Breen; R. Uher; C. M. Lewis

doi:10.1038/tp.2014.112

Investigation of blood mRNA biomarkers for suicidality in an independent sample

N. Mullins, K. Hodgson, K. E. Tansey, N. Perroud, W. Maier, O. Mors, M. Rietschel, J. Hauser, N. Henigsberg, D. Souery, K. Aitchison, A. Farmer, P. McGuffin, G. Breen, R. Uher, C. M. Lewis

Résultat de recherche: Article › examen par les pairs

12 Citations (Scopus)

Résumé

Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group, there was no significant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers.

Langue d'origine	English
Pages (de-à)	e474
Journal	Translational Psychiatry
Volume	4
DOI	https://doi.org/10.1038/tp.2014.112
Statut de publication	Published - 2014
Publié à l'externe	Oui

Note bibliographique

Funding Information:
The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. This work was funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London. This paper presents independent research in part funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CML has received funding from the European Community’s Seventh Framework Programme under the Marie Curie Industry-Academia Partnership and Pathways, grant agreement 286213. RU is supported by the Canada Research Chairs program (http://www.chairs-chaires.gc.ca/). KA holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta.

ASJC Scopus Subject Areas

Psychiatry and Mental health
Cellular and Molecular Neuroscience
Biological Psychiatry

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1038/tp.2014.112

Autres fichiers et liens

Citer

@article{691d3dde53674c90a29c3c1c73e7fcb1,

title = "Investigation of blood mRNA biomarkers for suicidality in an independent sample",

abstract = "Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group, there was no significant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers. ",

author = "N. Mullins and K. Hodgson and Tansey, {K. E.} and N. Perroud and W. Maier and O. Mors and M. Rietschel and J. Hauser and N. Henigsberg and D. Souery and K. Aitchison and A. Farmer and P. McGuffin and G. Breen and R. Uher and Lewis, {C. M.}",

note = "Funding Information: The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. This work was funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King{\textquoteright}s College London. This paper presents independent research in part funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CML has received funding from the European Community{\textquoteright}s Seventh Framework Programme under the Marie Curie Industry-Academia Partnership and Pathways, grant agreement 286213. RU is supported by the Canada Research Chairs program (http://www.chairs-chaires.gc.ca/). KA holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta.",

year = "2014",

doi = "10.1038/tp.2014.112",

language = "English",

volume = "4",

pages = "e474",

journal = "Translational Psychiatry",

issn = "2158-3188",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Investigation of blood mRNA biomarkers for suicidality in an independent sample

AU - Mullins, N.

AU - Hodgson, K.

AU - Tansey, K. E.

AU - Perroud, N.

AU - Maier, W.

AU - Mors, O.

AU - Rietschel, M.

AU - Hauser, J.

AU - Henigsberg, N.

AU - Souery, D.

AU - Aitchison, K.

AU - Farmer, A.

AU - McGuffin, P.

AU - Breen, G.

AU - Uher, R.

AU - Lewis, C. M.

N1 - Funding Information: The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. This work was funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London. This paper presents independent research in part funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CML has received funding from the European Community’s Seventh Framework Programme under the Marie Curie Industry-Academia Partnership and Pathways, grant agreement 286213. RU is supported by the Canada Research Chairs program (http://www.chairs-chaires.gc.ca/). KA holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta.

PY - 2014

Y1 - 2014

N2 - Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group, there was no significant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers.

AB - Changes in the blood expression levels of SAT1, PTEN, MAP3K3 and MARCKS genes have been reported as biomarkers of high versus low suicidality state (Le-Niculescu et al.). Here, we investigate these expression biomarkers in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, of patients with major depressive disorder on a 12-week antidepressant treatment. Blood gene expression levels were available at baseline and week 8 for patients who experienced suicidal ideation during the study (n=20) versus those who did not (n=37). The analysis is well powered to detect the effect sizes reported in the original paper. Within either group, there was no significant change in the expression of these four genes over the course of the study, despite increasing suicidal ideation or initiation of antidepressant treatment. Comparison of the groups showed that the gene expression did not differ between patients with or without treatment-related suicidality. This independent study does not support the validity of the proposed biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84979862340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979862340&partnerID=8YFLogxK

U2 - 10.1038/tp.2014.112

DO - 10.1038/tp.2014.112

M3 - Article

C2 - 25350297

AN - SCOPUS:84979862340

SN - 2158-3188

VL - 4

SP - e474

JO - Translational Psychiatry

JF - Translational Psychiatry

ER -

Investigation of blood mRNA biomarkers for suicidality in an independent sample

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer